title: BCR/ABL mRNA and the P210(BCR/ABL) protein are downmodulated by interferon-alpha in chronic myeloid leukemia patients.
abstract: The BCR/ABL hybrid gene plays a central role in the pathogenesis of the chronic phase of chronic myeloid leukemia (CML). We used a very sensitive quantitative reverse transcriptase-polymerase chain reaction to investigate the levels of hybrid BCR/ABL mRNA in bone marrow cells of 20 patients with Philadelphia positive (Ph(+)) CML treated with interferon-alpha (IFN-alpha) as a single agent. Bone marrow samples were collected at diagnosis and at hematologic remission induced by IFN-alpha, or by hydroxyurea in case of resistance to IFN-alpha. The mean levels of BCR/ABL transcripts in bone marrow mononuclear cells of patients who showed a complete hematologic response to IFN-alpha were significantly reduced with respect to those at diagnosis (48 x 10(3) v 168 x 10(3); P <.001), whereas no difference was detected between the values at diagnosis and at hematologic remission in patients resistant to IFN-alpha. In cell culture experiments, IFN-alpha priming significantly reduced the levels of BCR/ABL hybrid transcripts in a dose-dependent manner in Ph+ bone marrow precursors obtained at diagnosis from patients who subsequently responded to IFN-alpha treatment (P < .005). No downmodulation was observed in bone marrow precursors from patients who subsequently proved to be IFN-resistant. These results indicate that downmodulation of BCR/ABL gene expression could be one of the mechanisms involved in the response of CML patients to IFN-alpha treatment.
authors.affiliation: CEINGE-Biotecnologie Avanzate, Dipartimento di Biochimica e Biotecnologie Mediche and Divisione di Ematologia, Facoltá di Medicina, Universitá Federico II, Naples, Italy. fabpane@unina.it
authors.forename: F
authors.initials: F
authors.lastname: Pane
authors.forename: I
authors.initials: I
authors.lastname: Mostarda
authors.forename: C
authors.initials: C
authors.lastname: Selleri
authors.forename: R
authors.initials: R
authors.lastname: Salzano
authors.forename: A M
authors.initials: AM
authors.lastname: Raiola
authors.forename: L
authors.initials: L
authors.lastname: Luciano
authors.forename: G
authors.initials: G
authors.lastname: Saglio
authors.forename: B
authors.initials: B
authors.lastname: Rotoli
authors.forename: F
authors.initials: F
authors.lastname: Salvatore
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001854:Bone Marrow Cells / Q000378:metabolism / Q000473:pathology; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D016044:Fusion Proteins, bcr-abl / Q000235:genetics*; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D016898:Interferon-alpha / Q000627:therapeutic use*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D007958:Leukocyte Count; D009000:Monocytes / Q000378:metabolism / Q000473:pathology; D010677:Philadelphia Chromosome; D010976:Platelet Count; D012333:RNA, Messenger / Q000235:genetics; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014158:Transcription, Genetic
chemical_list: D000970:Antineoplastic Agents; D016898:Interferon-alpha; D012333:RNA, Messenger; D016044:Fusion Proteins, bcr-abl; D006918:Hydroxyurea